Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06564311 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Aug 2025 to Aug 28, 2025v17
  2. Trial status: Recruiting to Active, Not Recruiting Study sites: 49 to 47v16 Show 1 more changeShow less
    • Study sites: 49 to 47
  3. Study sites: 48 to 49v15
  4. Study sites: 42 to 48v14
  5. Site details revised at 1 of 42 sitesv13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 43 to 42v12
  2. Study sites: 30 to 43v11
  3. Completion date: Dec 2025 to Feb 2026 Study description expanded, about 24 wordsv10 Show 1 more changeShow less
    • Study description expanded, about 24 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 28 to 30v9
  5. Study sites: 24 to 28v8
  6. Study sites: 20 to 24v7
  7. Study sites: 9 to 20v6
  8. Study sites: 6 to 9v5
  9. Study sites: 4 to 6 Start date changed from estimate of Aug 2024 to Aug 26, 2024v4 Show 1 more changeShow less
    • Start date changed from estimate of Aug 2024 to Aug 26, 2024
  10. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4v3 Show 1 more changeShow less
    • Study sites: 0 to 4
  11. Primary endpoint revised Secondary endpoints revised (5) · Study title shortened, about 2 wordsv2 Show 2 more changesShow less
    • Secondary endpoints revised (5)
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Trial Details
NCT Number NCT06564311
Lead Sponsor Zenas BioPharma (USA), LLC
Conditions Relapsing Multiple Sclerosis
Enrollment 93 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov